Gilead and Merck’s latest trial success and flop
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
Read full article →Latest Healthcare Policy news from across the web.
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
Read full article →The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
Read full article →Opinions are divided about the new facility in Kenya. The U.S. defends it. Kenyans are protesting it. Doctors who were on the ground in the 2014 Ebola outbreak voice criticism as well.
Read full article →Research published in the American Journal of Public Health details the connection between ultra-processed foods and the tobacco industry when it comes to production, strategy and marketing.
Read full article →GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
Read full article →In this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.
Read full article →In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns.
Read full article →A suppressed federal alcohol report, an "inevitable development" for wearables data, and more health news from Morning Rounds
Read full article →As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
Read full article →Hospital execs say they're working to mitigate the impacts of the looming cuts.
Read full article →Is it “health care” or “healthcare”? STAT readers had strong feelings.
Read full article →Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
Read full article →